DaVita (DVA)
(Delayed Data from NYSE)
$139.01 USD
+0.87 (0.63%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $139.04 +0.03 (0.02%) 5:14 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.01 USD
+0.87 (0.63%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $139.04 +0.03 (0.02%) 5:14 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
CVS-Aetna Deal Leading a Wave of Change in Hospital Sector
by Zacks Equity Research
Increased consolidation is being witnessed in the hospital sector as a defense against invasion by new comers.
Company News For Dec 7, 2017
by Zacks Equity Research
Companies In The News are: PLAY,OXM,HRB,DVA,UNH
DaVita (DVA) Surges: Stock Moves 13.6% Higher
by Zacks Equity Research
DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes
UnitedHealth to Buy DaVita Medical, Expands Optum Business
by Zacks Equity Research
UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model
UnitedHealth Continues Healthcare Shakeup With DaVita Deal
by Benjamin Rains
On Wednesday, only a few days after the CVS (CVS) and Aetna (AET) deal helped shine a light on the quickly changing healthcare industry, UnitedHealth Group (UNH) announced that it will buy a unit of DaVita Inc. (DVA) for nearly $5 billion.
New Strong Sell Stocks for November 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
Should Value Investors Consider DaVita Inc. (DVA) Stock?
by Zacks Equity Research
Let's put DaVita Inc. (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.
DaVita HealthCare (DVA) Down 9.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval
by Zacks Equity Research
The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
by Zacks Equity Research
DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
On Jun 23, we issued an updated research report on Denver, CO-based DaVita HealthCare Partners Inc. (DVA).
Is DaVita a Suitable Stock for Value Investors?
by Zacks Equity Research
Let's focus on DaVita Inc. (DVA) stock and find out if it is a good choice for value-oriented investors right now or not.
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial
by Zacks Equity Research
DaVita Inc (DVA), through its subsidiary DaVita Clinical Research (DCR), recently announced the expansion of its research services to include Alliance Site Network.
DaVita (DVA): What's in the Cards this Earnings Season?
by Zacks Equity Research
DaVita HealthCare Partners Inc (DVA), is expected to report first-quarter fiscal 2017 results on May 2, after market close.
Why Is DaVita (DVA) Up 4.8% Since the Last Earnings Report?
by Zacks Equity Research
DaVita (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles
by Zacks Equity Research
DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.
DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4
by Zacks Equity Research
DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.
ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
ITT Inc. (ITT) is slated to report fourth-quarter 2016 results before the opening bell on Feb 14.
Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Allscripts Healthcare Solutions Inc. (MDRX) is scheduled to release fourth-quarter 2016 results on Feb 16.
Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.
Ecolab (ECL): What's in the Cards this Earnings Season?
by Zacks Equity Research
St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.
DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
by Zacks Equity Research
York, PA-based DENTSPLY Sirona Inc. (XRAY), a dental solutions company, is expected to report fourth-quarter 2016 results on Feb 10.
Will Q4 Earnings Hold a Surprise for DaVita (DVA) Stock?
by Zacks Equity Research
DaVita HealthCare Partners Inc. (DVA) is set to report fourth-quarter 2016 results after market close on Feb 9.